October 30, 2024 (MLN): Citi Pharma Ltd. (PSX: CPHL) recorded a 113.3% higher net profit in the first quarter of FY25 as its margins jumped.
The company earned a profit after tax of Rs201.5 million [EPS: Rs0.88] during the quarter ending September 2024, compared to Rs94.45m [EPS: Rs0.41] in the same period last year (SPLY).
Revenue expanded 19.4% to Rs3.22bn as compared to Rs2.7bn in SPLY. Gross profit surged 73.9% to Rs428.51m in Q1 FY25.
The gross margins improved to 13.3% as compared to 9.1% in SPLY.
During the period under review, other income shrank 13.2% to stand at Rs92.22m in Q1 FY25 as compared to Rs106.21m in SPLY.
On the expense side, the company's administrative expenses fell 3.9% from a year ago to Rs46.4m, selling and distribution expenses rose 5.3% to Rs40.7m, and other operating expenses rose 133.1% to Rs28.77m.
The company’s finance cost down by 25.6% and stood at Rs64.57m as compared to Rs86.81m in SPLY.
On the tax front, the company paid a higher tax worth Rs138.8m against an expense paid worth Rs72.17m in the corresponding period of last year, a rise of 92.3%.
This translates to an effective tax rate of 40.8% as compared to 43.3% in SPLY.
Unconsolidated (un-audited) Financial Results for quarter ended September 30, 2024 (Rupees in '000)
